Ireland's Minister of Health announces drug price cuts deal with industry
Ireland's Minister for Health, James Reilly, last week announced that agreement has been reached with the Irish Pharmaceutical Healthcare Association (IPHA) on interim drug price reductions. The price of certain off patent medicines are to be reduced which will deliver full year savings to the Health Services Executive (HSE) of 20 million euros ($25.5 million).
Under the recently expired Agreement between the HSE and IPHA, when a generic equivalent of an off patent medicine comes on the market, the price of the original product is reduced by 20% immediately and by a further 15% after 22 months.
IPHA agrees to 30% reduction on original when generic comes to market
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze